- Conditions
- Glioblastoma Multiforme
- Interventions
- BCNU Wafer, Irinotecan, Bevacizumab
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 708
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Drug
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- aldesleukin, autologous tumor cell vaccine, muromonab-CD3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Interventions
- ST101, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme
- Interventions
- FDOPA PET
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- adjuvant therapy, iodine I 125
- Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Glioblastoma
- Interventions
- Ivonescimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Avutometinib, Biospecimen Collection, Defactinib
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
- Interventions
- Niraparib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Recurrent Glioblastoma
- Interventions
- [18F]fluoromisonidazole, Bevacizumab, positron emission tomography (PET/CT).
- Biological · Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
- Interventions
- Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Jasper Gerritsen
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 464 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- San Francisco, California • Boston, Massachusetts
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
- Interventions
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Biological · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma Multiforme
- Interventions
- Avastin
- Drug
- Lead sponsor
- Brain & Spine Surgeons of New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma
- Interventions
- EGFRvIII-CARs
- Biological
- Lead sponsor
- Gary Archer Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- High Grade Glioma
- Interventions
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
- Conditions
- High Grade Glioma, Glioblastoma Multiforme
- Interventions
- DSP-0390
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Malignant Gliomas
- Interventions
- Irinotecan, Lenalidomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anaplastic Astrocytoma, Glioblastoma
- Interventions
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine
- Drug · Device · Procedure
- Lead sponsor
- Isarna Therapeutics GmbH
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Edison, New Jersey • Mineola, New York • Rochester, New York
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Grade III
- Interventions
- ADV/HSV-tk (gene therapy)
- Drug
- Lead sponsor
- David Baskin MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Everolimus, Surgery
- Drug · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Recurrent Glioblastoma IDH Wildtype
- Interventions
- D2C7-IT, 2141 V11
- Drug
- Lead sponsor
- Darell Bigner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor, Supratentorial Neoplasms
- Interventions
- Stem Cell Transplant
- Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 18 Months to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- Niraparib, Optune, Planned surgical resection
- Drug · Device · Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania